STOK SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 16, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Stoke Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Oct 29, 2026

8-K

Stoke Therapeutics Announces Board of Directors Resignation and Appointment

Sep 25, 2026

8-K

Stoke Therapeutics Files Prospectus Supplement for $200 Million At-the-Market Offering

Aug 3, 2026

8-K

Stoke Therapeutics Reports Q2 2026 Financial Results and Provides Business Updates

Aug 3, 2026

8-K

Stoke Therapeutics Completes Enrollment of Phase 3 EMPEROR Study for Zorevunersen

Jun 30, 2026

8-K

Stoke Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 4, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

[No Baby Shelf]* August 2026 ATM | Offering amount: $200,000,000 | Bank: Cantor Fitzgerald & Co.

Aug 3, 2026

424B5

OFFERING | Shares amount: 5,555,557 | Share price: $13.50 | Warrants amount: 3,703,730 | Offering amount: $125,000,004.00

Mar 28, 2024

424B5

OFFERING | Share price: $10.29 | Offering amount: $75,000,000.00

Mar 26, 2024

424B5

2,500,000 Shares

Nov 20, 2020

424B5

2,500,000 Shares

Nov 18, 2020

424B4

Common Stock

Jun 19, 2019

Registrations

TYPE

HEADLINE

FILED AT

S-8

Stoke Therapeutics, Inc. 2023 Inducement Plan Amendment

Aug 3, 2026

S-3ASR

March 2026 SHELF + ATM

Mar 18, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 16, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 9, 2025

S-3

July 2025 SHELF

Jul 9, 2025

DRS

Form DRS - Draft Registration Statement

Jun 26, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 22, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 22, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 22, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 22, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

Ticho Barry (Reporting)

Nov 4, 2026

144

Form 144 - Report of proposed sale of securities

Oct 21, 2026

Allan Jonathan (Reporting)

Oct 2, 2026

Ticho Barry (Reporting)

Oct 2, 2026

144

Form 144 - Report of proposed sale of securities

Oct 2, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 14, 2025

CORRESP

Form CORRESP - Correspondence

Jul 9, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jun 30, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 21, 2024

CORRESP

Form CORRESP - Correspondence

Jun 17, 2024

LETTER

Form UPLOAD - SEC-generated letter

Jun 17, 2024

Stoke Therapeutics, Inc. STOK · SEC Filings